Adcock Ingram climbs after positive HEPS forecast
Shares in the pharmaceutical manufacturer benefited after it said HEPS for the six months to end-December will be at least 27% higher than the previous period
Pharmaceutical manufacturer Adcock Ingram’s said on Tuesday that headline earnings per share (HEPS) for the six months to end-December will be at least 27%, or 40c, higher than the previous period.At 9.45am the company’s share price was up 1.68% at R61, having gained 4.54% so far in 2018.Earnings per share (EPS) would rise by at least 12%, with this lower figure attributable to non-trading capital profits the company received in October 2016. This related to Adcock’s disposal of its business interests in India.A more refined range of expected HEPS and EPS would be published in due course, the group said in a trading statement.Adcock, whose major market by turnover remains in SA, had reported HEPS of 148.6c for the half year to end-December 2016, declaring a cash dividend of 63c.
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.